BRIEF-Bristol Myers Reports Positive Phase 3 Results For Oral Mezigdomide In Relapsed Myeloma

Reuters03-09
BRIEF-Bristol Myers Reports Positive Phase 3 Results For Oral Mezigdomide In Relapsed Myeloma

March 9 (Reuters) - Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE PHASE 3 RESULTS FROM THE SUCCESSOR-2 STUDY OF ORAL MEZIGDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

  • BRISTOL-MYERS SQUIBB CO - MEZIKD DEMONSTRATES SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN RRMM

  • BRISTOL-MYERS SQUIBB CO - SAFETY FINDINGS CONSISTENT WITH KNOWN PROFILE OF MEZIGDOMIDE AND REGIMEN

Source text: ID:nBw8Ldl7La

Further company coverage: BMY.N

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment